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Abstract
I In nt tr ro od du uc ct ti io on n: :   Irritable bowel syndrome (IBS) is a prevalent gastrointestinal
disease with an obscure pathophysiology. Current treatments for IBS have
modest efficacy at best and the need for a robust therapy for IBS remains unmet.
As small intestinal bacterial overgrowth has been proposed to be involved in
pathogenesis of IBS, antibacterial agents might be efficacious in treatment of
this condition.  
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   PubMed, Embase, Scopus, Google Scholar, Web of
Science, and Cochrane Central Register of Controlled Trials were searched for
studies comparing the efficacy of antibiotics in the management of IBS and/or
IBS type symptoms. Data were collected from 1966 to April 2009. Clinical
response was considered as our key outcome of interest.
R Re es su ul lt ts s: :   Of five trials that evaluated the effect of antibiotics in IBS, two
randomized placebo-controlled trials met the inclusion criteria for the meta-
analysis. This meta-analysis included 234 patients with IBS-type symptoms of
whom 181 met the Rome criteria for IBS. The pooled relative risk (RR) for “clinical
response in IBS” was 2.04 (95% confidence interval [CI] of 1.23-3.40, p = 0.0061).
The pooled RR for “clinical response in IBS-type symptoms” was 2.06 (95% CI
of 1.3-3.27, p = 0.002).
C Co on nc cl lu us si io on ns s: :   Although antibiotics have a statistically significant effect on IBS
and  bloating,  given  the  evidence  for  the  presence  of  publication  bias,
methodological variability of the trials and lack of a precise scientific explanation
for the role of bacterial overgrowth in the pathophysiology of IBS, use of
antibiotics on a regular basis in IBS patients is not recommended.
K Ke ey y   w wo or rd ds s: : irritable bowel syndrome, antibiotics.
Introduction
Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder
characterized by chronic or recurrent abdominal pain and discomfort
associated with altered and alternating bowel habits. In addition, IBS
patients commonly complain of abdominal bloating, flatulence, dyspepsia
and incomplete evacuation [1].
Irritable bowel syndrome is present in up to 20% of the North American
population [2] and inflicts a significant impact on the health care system [3].
The pathophysiology of IBS remains obscure. Environmental factors
(psychological disturbances and stress), genetic links, recent infection, food
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intolerance, altered bowel motility and/or secretion,
visceral hypersensitivity, altered brain-gut sensory
processing  axis  and  enteric  neuromuscular
dysfunction are proposed as possible aetiological
factors for IBS [2, 4, 5]. The beneficial effects of
currently available approaches for management of
IBS are modest at best and there is a true need to
develop further efficacious therapeutic agents [6, 7].
Compared to the colon, the small bowel normally
contains relatively few bacteria. Once the small
bowel becomes populated by excessive bacteria (i.e.
small intestinal bacterial overgrowth [SIBO]), it leads
to various non-specific symptoms such as bloating,
flatulence, abdominal pain and watery diarrhoea
[8]. These symptoms are shared in a proportion of
IBS patients so one might contemplate that SIBO
is implicated in the pathogenesis of IBS. Moreover,
excessive intestinal gas has been radiographically
illustrated in IBS patients [9], which might explain
“bloating” as a prevalent clinical finding. This
phenomenon might be a result of increased gas
production secondary to bacterial fermentation in
SIBO. Subsequently, several randomized controlled
trials (RCTs) were conducted to evaluate the effect
of intestinal bacterial eradication with antibiotic
therapy in IBS patients [10-14].
As there is considerable controversy regarding
the use of antibiotics in IBS, we conducted this
study to systematically review and meta-analyze
the efficacy of antibiotics in adults with IBS and IBS-
type symptoms in placebo-controlled trials.
Material and methods
PubMed,  Embase,  Google  Scholar,  Web  of
Science, and Cochrane Central Register of Controlled
Trials were searched for studies that investigated
efficacy of anti-bacterial agents in IBS. Data were
collected from 1966 to April 2009. The search terms
were: “anti-bacterial”, “bacteriocidal”, “antibiotics”,
“anti-mycobacterial”, “rifaximin”, “metronidazole”,
“vancomycin”,  “gentamicin”,  “cephalosporin”,
“neomycin”, “norfloxacin”, “amoxicillin-clavulanate”,
“irritable bowel”, “functional bowel diseases” and
“irritable colon”. The search was restricted to English
literature. Reference lists of the retrieved articles
were also reviewed for additional applicable studies.
Controlled  trials  investigating  the  efficacy  of
antibiotics in patients with IBS were taken into
consideration. Clinical response was the key outcome
of interest for assessment of efficacy. We evaluated
all the published studies as well as the abstracts
presented at meetings. Two reviewers independently
examined the title and abstract of each article to
eliminate duplicates, reviews, case studies, and
uncontrolled trials. For the meta-analysis, trials were
disqualified if they were not placebo-controlled or
outcomes were not dichotomized into responders
and  non-responders.  Reviewers  independently
extracted data on patients’ characteristics, therapeutic
regimens, dosage, trial duration, and outcomes.
Disagreements, if any, were resolved by consensus.
Jadad score, which evaluates studies based on
their description of randomization, blinding, and
dropouts (withdrawals), was used to assess the
methodological quality of the trials [15]. The quality
scale ranges from 0 to 5 points with a low quality
report of score 2 or less and a high quality report
of score at least 3.
Data from selected studies were extracted into
2 × 2 tables. All included studies were weighted and
pooled. Data analysis was done using StatsDirect
(2.7.2).  Relative  risk  (RR)  and  95%  confidence
intervals (95% CI) were calculated using the Mantel-
Haenszel method. The Cochran Q test was used to
test heterogeneity. In addition, a L’Abbe plot was
used  to  explore  the  heterogeneity  of  effect
estimates and the presence of publication bias. 
F Fi in nd di in ng gs s
The primary literature search yielded 92 studies
from the aforementioned electronic databases. 
The process to select relevant studies is shown in
Figure 1. Five RCTs were found to have evaluated
the effect of antibiotics on IBS-type symptoms 
[10-14]. A study by Di Stefano et al. [14] compared
the effect of antibiotics versus charcoal on gas
46 excluded because of duplication
40 because of non-interventional
methodology
4 reports excluded upon full text review
n = 2: non-standard end points measured
n = 1: duplication
n =1: not placebo-controlled
2 eligible randomized controlled clinical trials
were included in the meta-analysis
92 potentially relevant reports identified 
and screened for retrieval from various
electronic search engines
6 reports retrieved
F Fi ig gu ur re e   1 1. .   Flow diagram of the study selection processArch Med Sci 1, February / 2010 51
The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis 
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Pimentel et al., 2003 12 1 4
Pimentel et al., 2006 22 1 5
Nayak et al, 1997 11 1 3
Sharara et al., 2006 22 1 5
T Ta ab bl le e   I I. . Jadad quality score of randomized controlled trials included in the meta-analysis
S St tu ud dy y   ( (n n) ) M Me ea an n    S Se ex x    L Lo os ss s   o of f    C Cr ri it te er ri ia a   t to o    T Tr re ea at tm me en nt t D Du ur ra at ti io on n   o of f   
a ag ge e F Fe em ma al le e M Ma al le e f fo ol ll lo ow w- -u up p   [ [% %] ] d di ia ag gn no os se e   I IB BS S f fo ol ll lo ow w- -u up p   p po os st t- -t tr re ea at tm me en nt t
Pimentel  43 61 50 9 Rome I Neomycin 500 mg  7 days
et al., 2003 twice daily for 10 days
Pimentel  39 58 29 8 Rome I Rifaximin, 400 mg thrice 10 weeks
et al., 2006 daily for 10 days
Nayak  N/A N/A N/A 0 Manning Metronidazole  50 days
et al., 1997  400 mg thrice daily 
(n = 30) for 10 days
Sharara  41 68 56 6* Rifaximin 10 days
et al., 2006 400 mg twice 
daily for 10 days
T Ta ab bl le e   I II I. .   Characteristics of papers included in the meta-analysis
production  in  patients  with  functional  bowel
disease. This study was excluded from our study as
it did not have a placebo arm. 
Jadad quality score, methodology and results of
the remaining four RCTs are summarized in Tables
I-III.  Except  for  one  study  [10]  data  regarding 
subtypes  of  IBS  (diarrhoea-predominant,
constipated-predominant  or  alternating  bowel
habits) were not available. The primary outcome
measure in the studies by Pimentel et al. [11] and
Nayak et al. [12] was the average improvement in
IBS composite clinical scores. As no conventional
dichotomous data (responder vs. non-responder)
were presented in these two studies, pooling the
results  with  the  other  trials  [10,  13]  was  not
statistically possible. Various clinical composite
scores were used in the trials (Table II); therefore,
meta-analysis  of  the  absolute  change  in  the
composite clinical scores was not practically possible.
Studies by Sharara et al. [13] and Pimentel et al.
[10] were included in the final meta-analysis. As
patients with IBS-type symptoms not meeting the
Rome criteria were also included in the trial by
Sharara et al. (Table II), the meta-analysis was
conducted once with all the patients in Sharara’s trial
and once with only the IBS subgroup. This meta-
analysis  included  234  patients  with  IBS-type
symptoms of whom 181 met the Rome criteria for IBS. 
The pooled relative risk (RR) for “clinical response
in IBS subgroup” [10, 13] was 2.04 (95% confidence
interval [CI] of 1.23-3.40, p = 0.0061, Figure 2).
Cochrane Q test suggested that the studies are
homogeneous (p = 0.4937); however, given the
small number of included studies, a random-effect
model was used for the meta-analysis. Regression
of normalized effect versus precision for all included
† Nayak et al. also included a third non-blinded arm (n = 15) treated with ispaghula, which provided better results in pain control, reduction 
of mucus in stool and rectosigmoid motility compared to metronidazole (results not shown)
* Rome II criteria were met in 56% of patients. Patients with bloating for more than 12 weeks with any of the symptoms of chronic abdominal
pain, disturbances in bowel movements or abnormal stool consistency were included in the study
Pimentel et al., 2003
Sharara et al., 2006
combined [random]
1.88 (1.09, 3.32)
2.97 (0.98, 9.49)
2.04 (1.23, 3.40)
F Fi ig gu ur re e   2 2. . Individual and pooled relative risk for the
outcome of “clinical response in IBS subgroup” in
the studies considering antibiotic vs. placebo therapy
Relative risk (95% confidence interval)
R Re el la at ti iv ve e   r ri is sk k   m me et ta a- -a an na al ly ys si is s   p pl lo ot t   ( (r ra an nd do om m   e ef ff fe ec ct ts s) )
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studies for clinical response among rifaximin vs.
placebo therapy could not be calculated because of
too few strata.
The pooled RR for “clinical response in IBS-type
symptoms” was 2.06 (95% CI of 1.3-3.27, p = 0.002,
Figure 3). Cochrane Q test suggested that the
studies are homogeneous (p = 0.5702); however,
given  the  small  number  of  included  studies,
a random-effect model was used for the meta-
analysis. Regression of normalized effect versus
precision for all included studies for clinical response
among antibiotics vs. placebo therapy could not be
calculated because of too few strata. Funnel plots
for the percentage of the improvements could not
be drawn due to absence of the corresponding
variances. None of the studies reported a significant
difference in adverse events among various arms.
Discussion
To our knowledge this is the first meta-analysis
of antibiotic therapy in IBS and IBS-type symptoms.
Irritable bowel syndrome patients who receive
antibiotics are two times more likely to experience
a clinical  response  within  the  first  10  days  of
treatment compared to those who received placebo
(Figure 2). Similar findings were observed in patients
with IBS-type symptoms, mainly flatulence, who
received antibiotics (Figure 3). These results are
statistically significant; however, several factors must
be considered to determine whether these results
bear clinical significance or practical relevance.
As  previously  noted,  the  main  assumption
behind the possible effectiveness of antibiotics in
IBS  is  the  presence  of  intestinal  bacterial
overgrowth. However, this hypothesis has been
subject to scepticism due to lack of scientific proof.
Unfortunately, except for small bowel cultures
which are impractical and expensive there is no
other reliable test to diagnose SIBO [16]. The lactose
hydrogen breath test (LHBT) may be alternatively
used as a surrogate marker for SIBO. Administration
of a test dose of lactulose in SIBO patients is
associated with an early rise in breath hydrogen
levels secondary to abnormal consumption of
lactulose by excessive small intestinal bacteria
followed by the normal later peak which is due to
metabolism of lactulose in the colon. 
There  is  a high  degree  of  variability  in  the
literature regarding the proportion of healthy subjects
and IBS patients with abnormal LHBT. Pimentel et al.
reported positive LHBT in up to 84% of IBS patients
[17]  compared  with  20%  in  healthy  controls. 
In contrast, Sharara et al. [13] and Parisi et al. [18],
using lactulose breath test and glucose breath test
respectively, found no abnormality in IBS patients.
Consistent with a study by Walters et al. [19], Bratten
et al. [20] reported a positive LHBT in 85% of healthy
subjects compared to 74% of IBS patients.
The lactulose hydrogen breath test has been
shown  to  have  a poor  sensitivity  (17%)  and
specificity (70%) to diagnose SIBO [21], with several
potential confounding factors capable of inducing
false positive results such as fast bowel transit.
Despite several technical limitations with LHBT
to diagnose SIBO, it is possible that alteration of
gut flora is responsible for IBS symptoms at least
in some patients.
Several studies have shown quantitative and
qualitative differences in intestinal bacterial flora
of  IBS  patients  compared  to  healthy  controls 
[22, 23]. Abnormal enteric bacterial flora may lead
to over-production of gas and changes in fatty acid
production which results in deconjugation of bile
salts  and  disruption  of  electrolyte  and  water
transport. The latter might affect bowel motility
with clinically significant symptoms. These findings
have  been  the  scientific  basis  for  the  use  of
probiotics in IBS [24, 25]. However, the majority of
enteric flora are still unculturable with current
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means and precise microbiological mapping of the
gut in IBS patients is far from being achieved. 
The  L’Abbe  plot  (Figure  4)  is  suggestive  of
publication bias with lack of negative small RCTs
(i.e. studies below the line of equality). Only Nayak
et al. reported a superior effect of placebo in the
first part of their study; however, in the second
phase of the trial metronidazole was superior to
placebo.  A definite  conclusion  regarding  the
presence of publication bias is elusive to achieve
as asymmetry of the plots may occur for various
other reasons [26]. Publication bias in functional
disorders  has  been  reported  previously  [27].
Therefore, our pooled relative risk might be an
overestimate of the true effect.
Two studies do not report dichotomous results
and  rather  reported  improvement  in  clinical
symptoms [11, 12]; however, if the hypothesis behind
these studies was “bacterial overgrowth as the cause
of IBS”, a conventional comparison of responders
versus non-responders would have been favoured.
Given the lack of a precise scientific explanation
for the role of gut flora in pathophysiology of IBS,
use of antibiotics on a regular basis in IBS patients
is not justified.
SIBO is not a true unifactorial disease; rather, it is
a consequence of an underlying dysmotility of the
bowels. The underlying cause of SIBO is usually not
reversible  and  recurrence  may  occur  after
discontinuation of antibiotics [28]. Thus, studies with
a longer period of follow-up are needed. Further
studies integrating reliable diagnostic approaches for
SIBO are needed. Emergence of the double balloon
study may pave the way to evaluate presence of
SIBO in IBS patients with jejunal aspirates, which is
a more reliable test for diagnosis of SIBO [16].
Despite a safe profile of antibiotics in the RCTs
included in this meta-analysis, it should also be kept
in mind that widespread use of antibiotics may
result in emergence of opportunistic bacterial
infections and bacterial resistance. Brigidi et al. have
reported isolation of rifaximin-resistant bacteria in
ulcerative colitis patients treated with 1800 mg/day
for a total period of 30 days [29]. 
In conclusion, it is possible that antibiotics have
some beneficial effects in IBS patients, especially
with  bloating  as  the  predominant  symptom.
However,  in  the  absence  of  a proven  patho-
physiological explanation for the role of antibiotics
in IBS, routine use of antibiotics in IBS and IBS-type
symptoms cannot be recommended. Larger studies
with standardized outcomes and reliable testing for
SIBO (e.g. glucose hydrogen testing) are required.
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